Senolytic drugs (or compounds) are a promising tool for reducing the impact of aging, potentially pushing the onset of the diseases of aging out into the far future. So how far along are we to deploying this potential tool for the average citizen’s benefit? There are only two drugs in practical pre-clinical studies, many more in development and animal studies. I found a good summary paper on this topic; the abstract is below with link to the full paper:

“Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic drugs Dasatinib, Quercetin, Fisetin and Navitoclax were discovered using a hypothesis‐driven approach. SC accumulate with ageing and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality and health expenditures. The most deleterious SC are resistant to apoptosis and have up‐regulation of anti‐apoptotic pathways which defend SC against their own inflammatory senescence‐associated secretory phenotype (SASP), allowing them to survive, despite killing neighbouring cells. Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue‐destructive SASP. Because SC take weeks to reaccumulate, senolytics can be administered intermittently – a ‘hit‐and‐run’ approach. In preclinical models, senolytics delay, prevent or alleviate frailty, cancers and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, haematological, metabolic and skin disorders as well as complications of organ transplantation, radiation and cancer treatment. As anticipated for agents targeting the fundamental ageing mechanisms that are ‘root cause’ contributors to multiple disorders, potential uses of senolytics are protean, potentially alleviating over 40 conditions in preclinical studies, opening a new route for treating age‐related dysfunction and diseases. Early pilot trials of senolytics suggest they decrease senescent cells, reduce inflammation and alleviate frailty in humans. Clinical trials for diabetes, idiopathic pulmonary fibrosis, Alzheimer’s disease, COVID‐19, osteoarthritis, osteoporosis, eye diseases and bone marrow transplant and childhood cancer survivors are underway or beginning. Until such studies are done, it is too early for senolytics to be used outside of clinical trials.”      [Full Paper: https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13141] This is very much worth reading; decide for yourself if the warning is worth heeding, but I have been using the protocol below for a couple of years with no negative impact.

I have been an early self-experimenter, and while I don’t have access to Dasatinib or Navitoclax, Life Extension has used an extract of fermented tea, Theaflavin Extract, as a substitute with nearly the same function and effectiveness in one of their senolytic products and I use that. My best result to date was using their Theaflavin Extract and Bio-Fisetin along with Liposomal Quercetin 500 mg from Senolyfe.com. When I say my best result, I am talking about feeling slightly under the weather for a few days starting on the third morning after completing the protocol: taking a month’s supply of all three in three days  (3 doses on an empty stomach between meals). I took that to mean I had killed stuff and was clearing out the toxins. The next time I did it, 3 months later, Senolyfe was out of stock, and the effect was not as noticeable.

To Your Greater Health and Fitness –

Frank